MD names David Haddock general counsel as Mary Ann Moore's Pediatrix exit takes formal shape
Pediatrix Medical Group (NYSE: MD) has a new name in the general counsel chair. David Haddock joins as Executive Vice President, General Counsel and Secretary at the Sunrise, Florida-based company, as Mary Ann Moore's departure, first flagged on May 1, 2026, moves from a calendar placeholder to a binding agreement. The separation agreement signed July 21 sets October 31 as Moore's last day with the organization.
Key takeaways
- David Haddock has joined Pediatrix Medical Group (NYSE: MD) as Executive Vice President, General Counsel and Secretary.
- Mary Ann Moore signed a separation agreement on July 21 setting October 31, 2026 as her last day, after her departure was first flagged on May 1, 2026.
- Pediatrix designates Moore's departure as a termination without cause under her Second Amended and Restated Employment Agreement, though the 8-K lists no dollar amounts.
- Haddock takes on three of Moore's four titles but not the Chief Administrative Officer role, and the filing does not say how that function will be covered.
- The 8-K was filed July 24 and signed by CFO Kasandra H. Rossi, with Haddock's appointment disclosed under Regulation FD in the same filing.
Pediatrix Medical Group (NYSE: MD) has a new name in the general counsel chair. David Haddock joins as Executive Vice President, General Counsel and Secretary at the Sunrise, Florida-based company, as Mary Ann Moore's departure, first flagged on May 1, 2026, moves from a calendar placeholder to a binding agreement. The separation agreement signed July 21 sets October 31 as Moore's last day with the organization.
The separation agreement
Moore's exit was already on the books. The May 1 disclosure said she would leave her combined role, which carried the Executive Vice President, General Counsel, Chief Administrative Officer and Secretary titles, before the end of 2026. The July 21 agreement, executed between Moore and PMG Services, Inc., a wholly-owned Pediatrix subsidiary, puts structure around that timeline: Moore serves in an advisory capacity through October 31, then separates completely. Pediatrix designates the departure as a termination without cause under Moore's Second Amended and Restated Employment Agreement with PMG, meaning Moore collects the benefits specified in that contract. The 8-K was filed July 24 and signed by Chief Financial Officer Kasandra H. Rossi. No dollar amounts appear in the document.
What Haddock inherits and what he does not
Haddock's appointment was disclosed under Regulation FD in the same filing. His title is Executive Vice President, General Counsel and Secretary, three of the four designations Moore held. The Chief Administrative Officer title does not appear alongside his name. The 8-K does not address how Pediatrix intends to cover that function or whether the responsibilities fold into an existing role. For investors watching MD's executive composition, that is the question the filing leaves open.
What to watch
October 31, 2026 is the definitive marker: Moore's advisory period closes, and her separation from Pediatrix Medical Group becomes effective on that date. Subsequent proxy filings are the next place to look for Haddock's compensation terms. Any decision on the Chief Administrative Officer vacancy would surface there or in a future 8-K.
Filed by the macro desk of MarketPR on July 25, 2026. Source: sec.gov. Indicative figures are not investment advice.